TRAT1 and neoplasm: These results are consistent with previous studies showing that IGHM (immunoglobulin heavy constant mu) gene expression correlates with a better prognosis for TNBC28, that immunostimulatory cytokine IL2 (interleukin 2) signaling through interaction with its receptor IL2RB (interleukin 2 receptor subunit beta) enhances the anti-tumor effects of NK cells29, and TRAT1 (T cell receptor associated transmembrane adaptor 1) is positivity associated with survival of melanoma patients30.